In the current cohort, there were 23.8% individuals still surviving to the last follow‐up, 57% cases with KPS ≥90, 42.8% patients at EGFR or ALK positive, and the vast majority of patients were lung adenocarcinoma. This evidence concerns the gene ALK and lung adenocarcinoma.